Immorta Bio, Inc.

Immorta Bio is a longevity biotech company developing stem-cell and senescent-cell therapies aimed at reversing biological aging and supporting regenerative healthspan.

Its stated mission centers on reversing aging, eliminating cancer, and rejuvenating organs, under the banner “Treating Diseases of Aging and Treating Aging As Disease.” The company’s lead technologies are SenoVax™, an autologous approach to clearing senescent cells, and StemCellRevivify™, which aims to rebuild damaged organs and tissues using stem cells.

Recent news includes selection for NYU Stern’s Endless Frontier Labs 2026-27 Life Sciences Cohort, a board appointment of former Ernst & Young health sciences partner Howard Brooks, and mouse lifespan-extension research accepted for presentation at AAI’s IMMUNOLOGY2026 meeting. Offices are in the Miami area, Florida.